Abstract A76: Immunologic changes following intraperitoneal administration of a formulated IL-12 plasmid in combination with standard neoadjuvant chemo in newly diagnosed advanced stage ovarian cancer patients

Author(s):  
Khursheed Anwer ◽  
Junko Matsuzaki ◽  
Wiam Bshara ◽  
Amit Lugade ◽  
Angela Omilian ◽  
...  
2015 ◽  
Vol 5 (4) ◽  
pp. 196 ◽  
Author(s):  
Lucas Minig ◽  
Cristina Zorrero ◽  
Pablo Padilla Iserte ◽  
Andres Poveda

2021 ◽  
Author(s):  
Malika Kengsakul ◽  
Gatske M. Nieuwenhuyzen-de Boer ◽  
Suwasin Udomkarnjananun ◽  
Stephen J. Kerr ◽  
Christa D. Niehot ◽  
...  

2015 ◽  
Vol 24 (6) ◽  
pp. 881-888 ◽  
Author(s):  
Hildegunn Høberg-Vetti ◽  
Cathrine Bjorvatn ◽  
Bent E Fiane ◽  
Turid Aas ◽  
Kathrine Woie ◽  
...  

2020 ◽  
Vol 7 (6) ◽  
pp. 1805094
Author(s):  
Maria Bååth ◽  
Sofia Westbom-Fremer ◽  
Laura Martin de la Fuente ◽  
Anna Ebbesson ◽  
Juliette Davis ◽  
...  

2010 ◽  
Vol 2010 ◽  
pp. 1-11 ◽  
Author(s):  
Marie-Claude Beauchamp ◽  
Amber Yasmeen ◽  
Ariane Knafo ◽  
Walter H. Gotlieb

Ovarian cancer is the most lethal of all gynecological malignancies, due in part to the diagnosis at an advanced stage caused by the lack of specific signs and symptoms and the absence of reliable tests for screening and early detection. Most patients will respond initially to treatment but about 70% of them will suffer a recurrence. Therefore, new therapeutic modalities are urgently needed to overcome chemoresistance observed in ovarian cancer patients. Evidence accumulates suggesting that the insulin/insulin growth factor (IGF) pathways could act as a good therapeutic target in several cancers, including ovarian cancer. In this paper, we will focus on the role of insulin/IGF in ovarian cancer tumorigenesis and treatment.


BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Xin Yan ◽  
Sanyuan Zhang ◽  
Junmei Jia ◽  
Jiaolin Yang ◽  
Yilai Song ◽  
...  

Abstract Background Ovarian cancer is a common cancer type in women and is often associated with onset of malnutrition. Total parenteral nutrition (TPN) is a nutritional intervention method that has been reported to have controversial effect on cancer patients. In the present retrospective study, we sought to explore the prevalence of malnutrition assessed by the Nutritional Risk Index (NRI) and its association with survival in advanced stage ovarian cancer patients. We also compared the post-operative outcome of the malnourished patients treated with either TPN or conservative management. Results A total of 415 patients with advanced stage ovarian cancer were separated into 4 nutrition groups based on the NRI scores. We found that a number of factors were significantly different among the 4 nutrition groups, including age, serum albumin level, BMI and NRI; among which serum albumin level and NRI were identified to be independent predictors of progression-free and overall survival. In the moderately and severely malnourished patients, those who were treated with TPN had significantly shorter hospitalization period, lower serum albumin level and lower BMI after surgery. In addition, serum albumin level, use of TPN and number of patients with complications were closely related to the hospital stay duration. Conclusion Malnutrition status is closely associated with survival of advanced stage ovarian cancer patients. These patients may benefit from TPN treatment for reduced hospitalization, especially with the onset of hypoalbuminemia.


Sign in / Sign up

Export Citation Format

Share Document